Novartis Revamps U.S. Pharma Unit, With New CEO Andre Wyss

Novartis is reorganizing its U.S. pharmaceutical business, effective May 1, a move that includes the departure of Ludwig Hanston, who ran the unit for the past two years, and the elimination of nearly 400 positions mostly at U.S. headquarters, the company's Global Pharma CEO David Epstein told employees in a memo distributed on April 13